Replies to post #211175 on Biotech Values

[DewDiligence]

RVNC 1Q17 CC prepared remarks:

https://www.sec.gov/Archives/edgar/data/1479290/000147929017000025/rvnc592017scriptex991.htm

[bladerunner1717]

re: RVNC

1Q17 cash used in operations was $21.2M.

2017 guidance for cash used in operations continues to be $102-112M, which implies $81-91M burn during the Apr-Dec 2017 9-month period and a cash balance at 12/31/17 of $61-71M (assuming no new financing transactions of revenue sources).

Why the big jump in the last three quarters of the year?


Bladerunner

[DewDiligence]

RVNC 2Q17 results:

https://finance.yahoo.com/news/revance-releases-second-quarter-2017-200500714.html

The 6/30/17 cash balance was $165.5M, a reduction of $4.2M relative to 3/31/17 (#msg-131213039). The small cash burn was due to use of the ATM facility—details will be available in the 2Q17 10-Q or on today’s CC.

Cash-usage guidance for full-year 2017 (excluding financing transactions) is unchanged at $102-112M.